Results 91 to 100 of about 411,617 (199)

Insulin Degludec [PDF]

, 2020
openaire   +1 more source

Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy

, 2019
Aims: The costs associated with insulin therapy and diabetes-related complications represent a significant and growing economic burden for healthcare systems.
Michael L. Wolden (6692944), Jens Gundgaard (3608846), Steffen Haldrup (3996431), Annunziata Lapolla (4421137)   +3 more
core   +1 more source

Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational study

Endocrine Regulations
Objective. In this retrospective observational study, we aimed to evaluate the impact of insulin degludec/insulin aspart (IDegAsp) treatment on glycemic status, metabolic parameters, and weight/body mass index (BMI) change at a single tertiary diabetes ...
Cakmak Ramazan, Caklili Ozge Telci, Kapar Caner, Catma Yunus, Bayramlar Osman Faruk, Calikoglu Fulya, Karsidag Kubilay, Dinccag Nevin   +7 more
doaj   +1 more source

Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis

Diabetes, Metabolic Syndrome and Obesity
Ruiqing Dong,1,* Lifan Gu,2,* Heping Li,1 Yuanna Hu,3 Hui Liu,4 Xuna Kou,1 Yukun Zhao,1 Meng Zhao,1 Bingyin Shi,1 Hui Guo,1 Wei Qiang1 1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi’an Jiaotong University,
Dong R, Gu L, Li H, Hu Y, Liu H, Kou X, Zhao Y, Zhao M, Shi B, Guo H, Qiang W   +10 more
doaj  

Concentrated insulins: the new basal insulins

Therapeutics and Clinical Risk Management, 2016
Elizabeth M Lamos,1 Lisa M Younk,2 Stephen N Davis3 1Division of Endocrinology, Diabetes and Nutrition, 2Department of Medicine, University of Maryland School of Medicine, 3Department of Medicine, University of Maryland Medical Center, Baltimore, MD ...
Lamos EM, Younk LM, Davis SN
doaj  

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide

Therapeutics and Clinical Risk Management, 2016
Molly G Minze,1 Lisa M Chastain2 1School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, 2Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA Abstract: The global burden
Minze MG, Chastain LM
doaj  

Cost-Effectiveness of Once-Weekly Insulin Icodec versus Daily Basal Insulins in Chinese Adults with T2DM: A Treatment-Background Stratified Analysis

ClinicoEconomics and Outcomes Research
Zeyu Xie,1 Weishang Deng,2 Zhuoru Liang,1 Yilin Xie,1 Jisheng Chen,3 Weiling Cao1 1Department of Pharmacy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen, Guangdong Province, People’s Republic of China ...
Xie Z, Deng W, Liang Z, Xie Y, Chen J, Cao W   +5 more
doaj  

A Novel Approach to Managing "Double Diabetes" in a Pediatric Patient on Insulin Pump Therapy: An Off-Label Use of a Fixed-Ratio Insulin Degludec/Liraglutide Combination. [PDF]

Cureus
Almoallem B, Thalange NK.
europepmc   +1 more source

Intra-Subject Variability in Pharmacokinetics and Pharmacodynamics of Basal Insulin at Two Single-Dose Levels: Findings from Euglycemic Glucose Clamp Bioequivalence Studies of Insulin Degludec. [PDF]

Pharmaceutics
Liu H, Li T, Chen X, Yu H, Men Y, Tan H, Li J, Yu Y.   +7 more
europepmc   +1 more source

Safety and Effectiveness of Insulin Degludec in Patients With Type 2 Diabetes Mellitus With Chronic Liver Disease. [PDF]

Cureus
Gupta V, Khurana G.
europepmc   +1 more source